Compare Amgen, Inc. (AMGN) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Wayfair Inc — how do they compare? Amgen, Inc. trades at $361.93 (market cap $196.12B), while Wayfair Inc trades at $88.66 (market cap $11.78B). The key difference: Amgen, Inc. is far larger — about 16.6× Wayfair Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.
| AMGN | W | |
|---|---|---|
Market Cap | $196.12B | $11.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $119.05 |
52-Week Low | $271.18 | $53.37 |
Enterprise Value | $241.41B | $14.35B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Wayfair (W) trades at $89.23, down 1.18% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $92.64. The company shows revenue growth to $12.46 billion in 2025 but remains unprofitable with a net loss of $313 million. Recent earnings beat expectations in Q3 and Q4 2025, while Q1 2026 matched estimates. Wayfair is expanding into brick-and-mortar stores and leveraging AI, as highlighted in recent Bloomberg coverage.
The stock presents a mixed outlook: analyst sentiment is positive with 52% buy ratings, but profitability challenges and high debt-to-asset ratio of 95% pose risks. Near-term catalysts include Q2 2026 earnings on August 4, 2026, and store expansion initiatives. Investors should weigh growth potential against persistent losses and competitive pressures in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
